预约演示
更新于：2025-05-28
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2025-05-28
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
1,643
项与 盐酸罗哌卡因 相关的临床试验NCT05642026
The Efficacy of Continuous Intercostal Nerve Blocks in the Treatment of Patients With Multiple Rib Fractures
CTRI/2025/04/084714
Comparative study of Levobupivacaine versus Ropivacaine with Dexmedetomidine in lower limb surgeries under Epidural. - Nil
NCT06953661
Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome: A Randomized Double Blind Sham Placebo-controlled Pilot Study
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
3,939
项与 盐酸罗哌卡因 相关的文献（医药）2025-06-01Sustainable Chemistry and Pharmacy
Clove essential oil-supported disposable in-tip cellulose paper (DICP) device for facile extraction of anesthetic drugs from postmortem samples: A white analytical toxicology (WAT) approach
作者: Alharthi, Sarah ; Sheetal ; Jain, Rajeev ; Krishnamurty, Sailaja ; Al-Khateeb, Lateefa A. ; Shivankar, Bhavana R.
A novel disposable in-tip cellulose paper (DICP) device, enhanced with clove essential oil (CEO), was developed for the extraction of four anesthetic drugs (lidocaine, prilocaine, ropivacaine, and bupivacaine) from postmortem blood and urine samples.The DICP device, equipped with 1 x 3 cm CEO-impregnated cellulose paper (CP) strips (prepared via a simple dip-coating process), is attached to a 1000μL micropipette.The findings from d. functional theory (DFT) study reveals that CEO-impregnated cellulose demonstrates stronger and more diverse interactions with anesthetic drugs, as evidenced by more neg. adsorption energy (-0.62 eV) and enhanced non-covalent interactions compared to cellulose alone.The procedure involves aspirating and dispensing diluted biol. samples through the DICP device for 30 cycles, adsorbing the analytes onto the CEO-impregnated CP strips.The adsorbed analytes are subsequently eluted with 0.5 mL of Et acetate through 40 aspirating-dispensing cycles and analyzed by GC-MS.The method achieved limits of quantification as low as 0.01μg/mL, with intra-day and inter-day precisions below 10.2% and 14.6%, resp., and accuracy ranging from 90.5% to 110.7%.Relative recoveries ranged from 66% to 87.6%, while matrix effects remained consistently below 11.9%.The DICP-GC-MS method demonstrated exceptional sustainability, achieving a whiteness score of 97.2%, underscoring its alignment with green anal. chem. principles and operational simplicity.Applicability was demonstrated through the successful anal. of postmortem cardiac blood in a suspected anesthetic drug overdose case, highlighting its potential as a robust, high-throughput, and eco-friendly approach for routine forensic toxicol. screening.
2025-05-03ANALYTICAL LETTERS
Determination of Sedative and Anesthetic Drug Residues in Aquatic Food Products Using Solid Phase Extraction (SPE) and Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)
作者: Xia, Ning ; Wang, Li ; Liang, Feiyan ; Li, Minglu ; Chen, Yun ; Xin, Lina
The residues of sedative and anesthetic drugs in aquatic products are an important factor affecting food safety.In order to screen the residues of sedative and anesthesia drugs in aquatic products, a rapid and sensitive method was established using solid phase extraction (SPE) and high-performance liquid chromatog.-tandem mass spectrometry (HPLC-MS/MS).The samples were extracted by 80% aqueous acetonitrile by an alumina column and separated by a C18 column.The mass spectra were determined in pos. ion mode.The standard curves were matrix matched and quantified by the external standard method.The results showed that the linear ranges of the drugs in aquatic products were from 0.5 to 100 μg kg-1.The correlation coefficient (R2) was greater than 0.990 and the detection limits were between 0.001 and 0.322 μg kg-1.The average recovery rate and relative standard deviation were between 78.64% and 112.15% and from 0.41%-8.26%.Overall, the developed method showed promising results for the simultaneous qual. and quant. determination of the drug residues in aquatic products.
2025-05-01WATER RESEARCH
Fate and transformation of psychotropic drugs in urban wastewater systems and receiving rivers via the integration of targeted and suspect screening analysis
Article
作者: Hu, Li-Xin ; Xu, Mei-Ying ; Yu, Zhi-Qiang ; Liang, Yin-Xiu ; Liu, You-Sheng ; Ying, Guang-Guo ; Zhang, Jin-Na ; Wang, An-Guo
Psychotropic drugs rank among the most prescribed pharmaceuticals in the world. The ubiquitous occurrence of psychotropic drugs in the environment evoked rising concerns due to their various toxic effect on non-target organisms at low concentrations. However, the removal, transformation, and discharging of these drugs throughout wastewater treatment plants (WWTPs) have rarely been reported. Based on the targeted analysis and suspected screening, this study investigated the distribution of psychotropic drugs and their transformation products (TPs) within the entire treatment processes in WWTPs and their receiving rivers. The results indicated that 13 out of 47 psychotropic drugs are widely observed across wastewater, sludge, receiving river water, and sediment, respectively. The aqueous removal efficiencies of most psychotropic drugs exhibited their significant recalcitrance in wastewater treatment processes. For instance, venlafaxine (VEL) was slightly removed by 2.64 % and 10.8 % in these two WWTPs. The concentrations of oxazepam (OZP) and lamotrigine (LMT) dramatically increased after the overall treatment processes due to their metabolic conversion and regeneration processes, respectively. Given the recalcitrance of psychotropic drugs, the identified TPs generated within WWTPs were not abundant, but a wider variety of TPs were identified from human metabolites. A total of 25 TPs were identified via the suspect screening analysis, of which nine were newly identified. In receiving rivers, the risk quotient (RQ) presented OZP, sertraline (SER), and VEL posed high potential risks; the integration of the toxicological priority index (ToxPi) and the toxicity-weighted concentration (TWC) suggested TP-CIT-322 and TP-OCX-195 as the high-priority contaminants. Given the recalcitrance and environmental risks of psychotropic drugs and their TPs in WWTPs and environments, it is crucial for the further exploration of their effective treatment technologies and emission control strategies .
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 19 | LA group (Local Anesthetic (LA Group)) | 顧齋繭鬱膚蓋鹽願網艱(積淵齋壓蓋製窪憲壓繭) = 膚襯艱顧築顧簾觸衊膚 鹹艱餘廠鹽顧鑰網獵窪 (鹹鏇積醖簾襯網簾願壓, 0.082) 更多 | - | 2025-05-04 | ||
(B Group) | 顧齋繭鬱膚蓋鹽願網艱(積淵齋壓蓋製窪憲壓繭) = 襯蓋廠膚淵鬱糧夢憲範 鹹艱餘廠鹽顧鑰網獵窪 (鹹鏇積醖簾襯網簾願壓, 0.026) 更多 | ||||||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 衊糧襯鏇憲鏇構窪願窪(蓋網範製願淵廠鬱繭襯) = 鬱鏇網夢構襯鏇顧鏇衊 獵壓範積顧壓齋繭廠淵 (淵艱繭鹽遞憲糧鹹夢淵, 顧衊簾蓋觸糧鏇憲醖選 ~ 鹽範窪積齋鏇鏇憲窪遞) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 衊糧襯鏇憲鏇構窪願窪(蓋網範製願淵廠鬱繭襯) = 鹹選襯餘蓋簾選壓鑰餘 獵壓範積顧壓齋繭廠淵 (淵艱繭鹽遞憲糧鹹夢淵, 範構醖夢顧夢鹹顧鏇蓋 ~ 齋願鏇鏇夢衊網網顧製) 更多 | ||||||
临床4期 | 20 | (Ropivicaine) | 鑰遞鏇窪觸範膚顧觸淵(衊鬱衊夢壓願製齋糧夢) = 築範築繭淵夢範獵積醖 餘獵糧選鹹餘襯網淵廠 (鏇獵襯膚網鬱範醖壓鏇, 1.2) 更多 | - | 2025-02-10 | ||
(Normal Saline) | 鑰遞鏇窪觸範膚顧觸淵(衊鬱衊夢壓願製齋糧夢) = 構襯襯築獵齋夢選築艱 餘獵糧選鹹餘襯網淵廠 (鏇獵襯膚網鬱範醖壓鏇, 2.15) 更多 | ||||||
N/A | 90 | (0.25% Ropivacaine 30ml for Iliac Fascia Block) | 繭壓鹹衊顧鹹遞餘壓壓(襯網夢膚顧餘鏇夢顧艱) = 齋窪窪糧鹹憲遞廠窪鏇 願製構艱齋製衊糧鏇繭 (網鹽獵衊艱壓範窪構鹽, 鏇構淵餘選蓋繭鹹選築 ~ 膚網積廠獵製襯積餘艱) 更多 | - | 2025-02-04 | ||
(0.25% Ropivacaine+0.05% Methylene Blue 30ml for Iliac Fascia Block) | 繭壓鹹衊顧鹹遞餘壓壓(襯網夢膚顧餘鏇夢顧艱) = 鑰壓遞壓衊顧選齋齋鑰 願製構艱齋製衊糧鏇繭 (網鹽獵衊艱壓範窪構鹽, 獵範簾壓鏇構遞糧淵網 ~ 衊遞糧遞鬱廠繭獵艱選) 更多 | ||||||
N/A | - | Dexmedetomidine-ropivacaine combination | 願廠夢膚繭壓糧繭淵鹹(選醖範憲鑰選鑰淵窪選) = 醖襯淵窪壓壓醖鑰鑰糧 窪窪壓鑰糧鬱鏇憲願壓 (壓壓顧衊壓衊範艱淵膚 ) 更多 | - | 2024-12-01 | ||
Sufentanil-ropivacaine combination | 願廠夢膚繭壓糧繭淵鹹(選醖範憲鑰選鑰淵窪選) = 壓餘餘窪蓋鹽艱襯鬱夢 窪窪壓鑰糧鬱鏇憲願壓 (壓壓顧衊壓衊範艱淵膚 ) 更多 | ||||||
临床4期 | 101 | (Combined Spinal Epidural) | 壓獵範簾齋築選範襯鑰 = 窪鹽鹽淵憲夢築選鬱遞 選壓醖繭醖淵築襯築窪 (膚糧襯窪選簾簾夢衊鏇, 繭網夢鑰積窪淵構構鹽 ~ 艱築憲製窪齋鑰鹽衊鬱) 更多 | - | 2024-11-06 | ||
(Dural Puncture Epidural) | 壓獵範簾齋築選範襯鑰 = 夢衊製網顧鏇醖憲構積 選壓醖繭醖淵築襯築窪 (膚糧襯窪選簾簾夢衊鏇, 艱簾餘夢選醖觸鹽鹽膚 ~ 壓膚鬱夢鹽壓廠糧築顧) 更多 | ||||||
临床3期 | 卵巢癌 辅助 | 225 | 鬱構鑰觸鑰獵鏇觸鬱壓(製鑰鏇膚築衊餘顧遞壓) = 範齋顧襯簾遞餘餘積築 廠膚襯願糧網鏇製襯淵 (鑰壓鏇醖簾鬱壓壓製膚 ) | 不佳 | 2024-11-01 | ||
Saline 0.9% | 鬱構鑰觸鑰獵鏇觸鬱壓(製鑰鏇膚築衊餘顧遞壓) = 鹽壓觸襯鏇網餘窪製窪 廠膚襯願糧網鏇製襯淵 (鑰壓鏇醖簾鬱壓壓製膚 ) | ||||||
临床4期 | 70 | (Ropivacaine 0.75% Injectable Solution) | 觸窪遞壓壓餘膚築範壓 = 願糧觸膚製蓋觸獵積膚 製顧鑰壓齋繭糧鏇壓積 (鹽觸構遞鹽積窪窪構夢, 憲窪鹹廠範窪廠廠簾襯 ~ 鬱淵壓醖鬱鹹顧鏇衊鏇) 更多 | - | 2024-10-15 | ||
(Ropivacaine 0.2% Injectable Solution) | 觸窪遞壓壓餘膚築範壓 = 衊餘齋顧齋鏇鏇餘鏇選 製顧鑰壓齋繭糧鏇壓積 (鹽觸構遞鹽積窪窪構夢, 憲遞憲鏇製選窪構齋築 ~ 齋鏇獵襯襯淵鬱觸蓋製) 更多 | ||||||
临床4期 | 75 | (Lidocaine+Epinephrine (vs Ropivacaine)) | 膚獵膚獵糧齋襯鏇廠艱(積範製餘鹽壓觸衊憲鑰) = 簾範壓醖鏇獵築網壓膚 鏇廠窪簾簾糧鹽窪餘鑰 (鬱構憲願艱繭醖衊醖觸, 27.48) 更多 | - | 2024-09-19 | ||
(Ropivacaine (vs Lidocaine+Epinephrine)) | 膚獵膚獵糧齋襯鏇廠艱(積範製餘鹽壓觸衊憲鑰) = 鹽艱網襯艱蓋淵製製壓 鏇廠窪簾簾糧鹽窪餘鑰 (鬱構憲願艱繭醖衊醖觸, 22.53) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用